BFG
IBRX icon

Bleakley Financial Group’s ImmunityBio IBRX Stock Holding History

Bleakley Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
129,381
-34,191
-21% -$259K 0.01% 615
2026
Q1 		$1.25M Buy
+163,572
New +$1.12M 0.02% 475
2025
Q1 		– Sell
-14,095
Closed -$36.1K – 724
2024
Q4 		$36.1K Sell
14,095
-1,848
-12% -$7.7K ﹤0.01% 1030
2024
Q3 		$59.3K Buy
15,943
+137
+0.9% +$634 ﹤0.01% 995
2024
Q2 		$99.9K Buy
15,806
+4,983
+46% +$32.9K ﹤0.01% 952
2024
Q1 		$58.1K Buy
+10,823
New +$49K ﹤0.01% 958

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bleakley Financial Group's IBRX Position: Q2 2026 in Review

Bleakley Financial Group reduced its ImmunityBio (IBRX) stake by 21% in Q2 2026, selling an estimated $259K and leaving 129,381 shares worth $1.13M. The position accounts for 0.01% of the portfolio, ranked #615.

Bleakley Financial Group first reported a position in IBRX in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.25M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Bleakley Financial Group held 129,381 shares of ImmunityBio worth $1.13M as of Q2 2026.
  • Bleakley Financial Group sold 34,191 ImmunityBio shares in Q2 2026, an estimated $259K.
  • ImmunityBio made up 0.01% of Bleakley Financial Group's portfolio in Q2 2026, its #615 holding.
  • Bleakley Financial Group first reported a position in ImmunityBio in Q1 2024 and has held it in 6 quarters since.
  • Bleakley Financial Group's ImmunityBio position peaked at $1.25M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.